Journal article
Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications
Pharmaceuticals (Basel, Switzerland), Vol.3(6), pp.1909-1935
2010
DOI: 10.3390/ph3061908
PMCID: PMC2904466
PMID: 20640233
Abstract
In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not been established in clinical trials for these new anticonvulsants, and clear guidelines for drug monitoring have yet to be defined. The antiepileptic drugs with the strongest justifications for drug monitoring are lamotrigine, oxcarbazepine, stiripentol, and zonisamide. Stiripentol and tiagabine are strongly protein bound and are candidates for free drug monitoring. Therapeutic drug monitoring has lower utility for gabapentin, pregabalin, and vigabatrin. Measurement of salivary drug concentrations has potential utility for therapeutic drug monitoring of lamotrigine, levetiracetam, and topiramate. Therapeutic drug monitoring of the new antiepileptic drugs will be discussed in managing patients with epilepsy.
Details
- Title: Subtitle
- Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications
- Creators
- Matthew D Krasowski - Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, RCP 6233, Iowa City, IA 52242, USA; E-Mail
- Resource Type
- Journal article
- Publication Details
- Pharmaceuticals (Basel, Switzerland), Vol.3(6), pp.1909-1935
- DOI
- 10.3390/ph3061908
- PMID
- 20640233
- PMCID
- PMC2904466
- NLM abbreviation
- Pharmaceuticals (Basel)
- ISSN
- 1424-8247
- eISSN
- 1424-8247
- Publisher
- MDPI
- Language
- English
- Date published
- 2010
- Academic Unit
- Pathology
- Record Identifier
- 9984046803802771
Metrics
20 Record Views